Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs
Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-Cell Transfusion in HLA-Matched Living Donor Kidney Transplantation
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
A PHASE1/PHASE2 clinical study on Immune Tolerance, this trial is ongoing. The trial is conducted by National Heart, Lung, and Blood Institute (NHLBI) and has accumulated 8 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Apr 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting · Phase: PHASE1 → PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jul 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
- Stanford University
For direct contact, visit the study record on ClinicalTrials.gov .